Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus TACE for Intermediate-stage HCC
NCT04842565Phase 2Completed
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started May 2021; status: completed.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04842565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842565.